No Data
No Data
No Data
On April 26, Heyu-B (02256) spent about HK$472,400 to buy back 149,000 shares
Goodwill B (02256) announced that on April 26, 2024, it cost approximately HK$472,400 to buy back 14.9...
Hong Kong Stock Announces Nuggets | CNOOC achieved net profit of 39.719 billion yuan in the first quarter, up 23.7% year-on-year
[Important matters] Xintong Medical-B (02160): Vitaflow Liberty received CE mark approval and honor-b (02256): FGFR4 inhibitor ipagotinib was certified as an orphan drug by the US FDA China Biopharmaceutical (01177): Class 1 innovative drug “TQA3038 (siRNA)” completed phase I clinical research Huatai Securities (06886) plans to cash out about US$1,793 million in China's Xincheng (01278) subsidiary investment of 5000 10,000 yuan acquisition of Meidi Pension Service
Abbisko Cayman's Liver Cancer Drug Gets US FDA Orphan Drug Designation
The US Food and Drug Administration granted orphan drug designation to Abbisko Cayman's (HKG:2256) irpagratinib medication for hepatocellular carcinoma or liver cancer, according to a Thursday filing
Repurchase Collection on April 24 | HSBC Holdings, Hang Seng Bank, etc. bought back one after another, of which HSBC Holdings spent HK$82,6392 million
According to HKEx's April 25 disclosure documents, $HSBC Holdings (00005.HK) $ and $Hang Seng Bank (00011.HK) $ repurchased shares. ① $HSBC Holdings (00005.HK) $ repurchased 1,285,200 common shares on April 23, involving an amount of HK$82,6392 million. The repurchase price per share ranged from HK$64.65 to HK$64.05. ② $Hang Seng Bank (00011.HK) $ repurchased 600,000 common shares on April 24, involving an amount of HK$597.95 million, with a repurchase price of HK$100.3 per share
Goodwill B (02256): The FGFR4 inhibitor ipagotinib was certified as an orphan drug by the US FDA
Heyu-B (02256) issued an announcement. The company's subsidiary, Shanghai Heyu Biomedical Technology Co., Ltd. (Heyu...
Goodwill B (02256.HK) spent HK$156,000 to buy back 51,000 shares on April 24
On April 24, Gelonghui (02256.HK) announced that it spent HK$156,000 to buy back 51,000 shares on April 24.
No Data